This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Bayer (BAYRY) Gets a Boost With Product Approvals and Deals
by Zacks Equity Research
Bayer (BAYRY) gets a boost as it wins approvals for a few candidates and enters into collaboration agreements.
Bayer (BAYRY) Inks Deal With Atara for CAR-T Cell Therapies
by Zacks Equity Research
Bayer (BAYRY) inks a deal with Atara to sell the latter's to -generation, mesothelin-directed CAR-T cell therapies for the treatment of solid tumors.
Company News for Sep 14, 2020
by Zacks Equity Research
Companies In The News Are: RIO, ATRA, NKLA, LAUR, ATGE.
Atara (ATRA) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Atara (ATRA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Why Atara Biotherapeutics (ATRA) Might Surprise This Earnings Season
by Zacks Equity Research
Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will Atara Biotherapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Atara Biotherapeutics
Is Atara Biotherapeutics (ATRA) Stock a Solid Choice Right Now?
by Zacks Equity Research
Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Atara Biotherapeutics (ATRA) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Why Atara Biotherapeutics (ATRA) Stock Might be a Great Pick
by Zacks Equity Research
Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will Atara Biotherapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Atara Biotherapeutics
Trade Deal Optimism Fuels Santa Rally: ETFs & Stocks to Bet On
by Sweta Killa
Trade deal optimism coupled with the Santa Claus rally have turned the market super bullish for the last five trading days left this year.
5 Beaten-Down Biotech Stocks Set to Rebound in 2020
by Kinjel Shah
Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Options Traders Betting on a Big Move in Atara (ATRA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Atara (ATRA) stock based on the movements in the options market lately.
Atara Reports Initial Data for Multiple Sclerosis Candidate
by Zacks Equity Research
Atara (ATRA) announces initial ATA188 phase I safety results for patients with progressive MS.
Company News For Jan 4, 2019
by Zacks Equity Research
Companies in the news are: BMY, CELG, DAL, TRCO and ATRA
Atara Biotherapeutics (ATRA) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Atara Biotherapeutics (ATRA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Is a Beat in the Cards for Celldex (CLDX) in Q4 Earnings?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on immuno-oncology pipeline.
What's in Store for Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme is expected to provide updates on the development of its pipeline candidates during Q4 earnings call.
What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?
by Zacks Equity Research
We expect Immune Design (IMDZ) to shed light on the progression of the trails on pipeline candidates when it releases fourth-quarter earnings results on Mar 6.
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Investor focus are likely to remain on Intrexon's (XON) performance along with other developmental updates during the quarterly call.
Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.